Melanoma Specialty Channel

News

Nivolumab Plus Relatlimab Demonstrates Long-Term Efficacy, Safety Among Newly Diagnosed Patients With Advanced Unresectable Melanoma

08/19/2025

Stephanie Holland

According to results from the phase 2/3 RELATIVITY-047 trial, nivolumab plus relatlimab demonstrated durable long-term efficacy and safety among newly diagnosed patients with advanced unresectable melanoma.

According to results from the...

08/19/2025

Oncology

Conference Coverage

Neoadjuvant Dostarlimab Plus Cobolimab Demonstrates Promise Among Patients With High-Risk Resectable Melanoma

08/12/2025

Meghan Mooradian, MD

Meghan Mooradian, MD, discusses primary analysis results from the phase 2 NEO-MEL-T trial, which showed that neoadjuvant dostarlimab plus cobolimab demonstrated promising efficacy and safety among patients with high-risk resectable melanoma.

Meghan Mooradian, MD, discusses...

08/12/2025

Oncology

Conference Coverage

First-Line Encorafenib Plus Binimetinib and Nivolumab for Patients With BRAF-Mutated Melanoma Brain Metastases

07/24/2025

Zeynep Eroglu, MD

Zeynep Eroglu, MD, discusses results from the SWOG S2000 study which demonstrated that encorafenib plus binimetinib and nivolumab significantly improved progression-free survival compared to ipilimumab plus nivolumab among patients with...

Zeynep Eroglu, MD, discusses...

07/24/2025

Oncology

Conference Coverage

Addition of Relatimab to Nivolumab Did Not Significantly Improve Outcomes for Patients With Melanoma

07/24/2025

Georgina Long, MBBS, PhD

Georgina Long, MD, PhD, discusses primary results from the RELATIVITY-098 trial, which demonstrated that adjuvant nivolumab plus relatimab did not significantly improve outcomes compared to adjuvant nivolumab monotherapy among patients with...

Georgina Long, MD, PhD,...

07/24/2025

Oncology

Conference Coverage

Adjuvant Encorafenib Plus Binimetinib Demonstrates Promise Among Patients With BRAF-Mutated Melanoma

07/24/2025

Alexander Van Akkooi, MD, PhD

Alexander Van Akkooi, MD, PhD, discusses primary analysis results from the EORTC 2139-MG/Columbus-AD trial which demonstrated that adjuvant encorafenib plus binimetinib demonstrates clinical promise among patients with BRAF-mutated melanoma.

Alexander Van Akkooi, MD, PhD,...

07/24/2025

Oncology

Conference Coverage

Neoadjuvant Pembrolizumab for Treatment-Naive Patients With Stage IIB/IIC Melanoma

06/17/2025

Stephanie Holland

According to results from a multicenter, phase 2 trial, neoadjuvant pembrolizumab demonstrated both efficacy and safety among patients with stage IIB/IIC melanoma without risking increased sentinel lymph node metastasis.

According to results from a...

06/17/2025

Oncology

News

Adjuvant Pembrolizumab Continues to Prolong Survival Outcomes Among Patients With Stage IIB/IIC Melanoma

05/12/2025

Stephanie Holland

According to long-term follow-up results from the KEYNOTE-716 trial, adjuvant pembrolizumab continued to prolong survival outcomes among patients with stage IIB/IIC melanoma.

According to long-term follow-up...

05/12/2025

Oncology

News

Addition of Short-Term Targeted Therapy Provides Long-Term Survival Benefit for Patients With Advanced Melanoma

05/06/2025

Stephanie Holland

According to updated survival results from the IMPemBra trial, the addition of short-term targeted therapy to anti-PD1 inhibition demonstrated long-term survival benefit among treatment-naive patients with BRAFV600E/K-mutated advanced...

According to updated survival...

05/06/2025

Oncology

News

Tilsotolimod Plus Ipilimumab Fails to Significantly Improve Outcomes for Patients With Advanced Refractory Melanoma

04/11/2025

Stephanie Holland

According to results from the phase 3 ILLUMINATE-301 study, the addition of tilsotolimod to ipilimumab did not significantly improve outcomes among patients with advanced refractory melanoma.

According to results from the...

04/11/2025

Oncology

News

Pembrolizumab Plus Bevacizumab Shows Promise Among Previously Untreated Patients With Melanoma Brain Metastases

04/01/2025

Stephanie Holland

According to results from a phase 2 study, pembrolizumab plus bevacizumab demonstrated promise among previously untreated patients with melanoma brain metastases.

According to results from a...

04/01/2025

Oncology

News

Ipilimumab Plus Nivolumab Sustains Efficacy Among Patients With Asymptomatic Melanoma Brain Metastases

03/10/2025

Stephanie Holland

According to long-term follow-up results from a phase 2 study, ipilimumab plus nivolumab demonstrated long-term efficacy among immunotherapy-naive patients with asymptomatic melanoma brain metastases.

According to long-term follow-up...

03/10/2025

Oncology

News

Nivolumab Plus Relatlimab Demonstrates Long-Term Efficacy, Safety Among Newly Diagnosed Patients With Advanced Unresectable Melanoma

08/19/2025

Stephanie Holland

According to results from the...

08/19/2025

Oncology

Conference Coverage

Neoadjuvant Dostarlimab Plus Cobolimab Demonstrates Promise Among Patients With High-Risk Resectable Melanoma

08/12/2025

Meghan Mooradian, MD

Meghan Mooradian, MD, discusses...

08/12/2025

Oncology

Conference Coverage

First-Line Encorafenib Plus Binimetinib and Nivolumab for Patients With BRAF-Mutated Melanoma Brain Metastases

07/24/2025

Zeynep Eroglu, MD

Zeynep Eroglu, MD, discusses...

07/24/2025

Oncology

Conference Coverage

Addition of Relatimab to Nivolumab Did Not Significantly Improve Outcomes for Patients With Melanoma

07/24/2025

Georgina Long, MBBS, PhD

Georgina Long, MD, PhD,...

07/24/2025

Oncology

Conference Coverage

Adjuvant Encorafenib Plus Binimetinib Demonstrates Promise Among Patients With BRAF-Mutated Melanoma

07/24/2025

Alexander Van Akkooi, MD, PhD

Alexander Van Akkooi, MD, PhD,...

07/24/2025

Oncology

Conference Coverage

Neoadjuvant Pembrolizumab for Treatment-Naive Patients With Stage IIB/IIC Melanoma

06/17/2025

Stephanie Holland

According to results from a...

06/17/2025

Oncology

News

Adjuvant Pembrolizumab Continues to Prolong Survival Outcomes Among Patients With Stage IIB/IIC Melanoma

05/12/2025

Stephanie Holland

According to long-term follow-up results from the KEYNOTE-716 trial, adjuvant pembrolizumab continued to prolong survival outcomes among patients with stage IIB/IIC melanoma.

According to long-term follow-up...

05/12/2025

Oncology

News

Addition of Short-Term Targeted Therapy Provides Long-Term Survival Benefit for Patients With Advanced Melanoma

05/06/2025

Stephanie Holland

According to updated survival...

05/06/2025

Oncology

News

Tilsotolimod Plus Ipilimumab Fails to Significantly Improve Outcomes for Patients With Advanced Refractory Melanoma

04/11/2025

Stephanie Holland

According to results from the phase 3 ILLUMINATE-301 study, the addition of tilsotolimod to ipilimumab did not significantly improve outcomes among patients with advanced refractory melanoma.

According to results from the...

04/11/2025

Oncology

News

Pembrolizumab Plus Bevacizumab Shows Promise Among Previously Untreated Patients With Melanoma Brain Metastases

04/01/2025

Stephanie Holland

According to results from a phase 2 study, pembrolizumab plus bevacizumab demonstrated promise among previously untreated patients with melanoma brain metastases.

According to results from a...

04/01/2025

Oncology

Interactive Features

Quiz

Quiz: Does Pembrolizumab Plus Ipilimumab Lead to Antitumor Activity in Melanoma?

08/26/2021

True or false: In a recent phase 2 trial, pembrolizumab plus low-dose ipilimumab demonstrated antitumor activity and tolerability for patients with melanoma after anti-PD-1 immunotherapy failure.

True or false: In a recent phase...

08/26/2021

Oncology

Test Your Knowledge

Quiz: Nomograms Developed to Predict Recurrences in Patients with T1 Melanomas

03/26/2021

True or False: The nomograms in this study can identify T1 melanoma patients at higher risk of either local, regional or distant recurrence.

True or False: The nomograms in...

03/26/2021

Oncology

Test Your Knowledge

Quiz: Combining Low-Dose Ipilimumab With Pembrolizumab in Melanoma

06/22/2020

True or False: In a phase 2 study, combining low-dose ipilimumab with pembrolizumab led to significant antitumor activity in patients with melanoma that progressed with a PD1 antibody.

True or False: In a phase 2...

06/22/2020

Oncology

Test Your Knowledge

Quiz: What Factors Increase Risk for AEs in Patients With Melanoma?

05/25/2020

True or False: The risk for immune-related adverse events in patients with advanced melanoma varies based on immune checkpoint inhibitor type and dose.

True or False: The risk for...

05/25/2020

Oncology

Test Your Knowledge

Quiz: Can Adverse Events Indicate Pembrolizumab Activity in Stage III Melanoma?

03/06/2020

True or False: Immune-related adverse events can be indicative of pembrolizumab activity in patients with high-risk, stage III melanoma.

True or False: Immune-related...

03/06/2020

Oncology

Test Your Knowledge

Quiz: Mohs Micrographic Surgery vs Traditional Excision for Melanoma

02/13/2020

True or False: Compared with excision, Mohs micrographic surgery moderately improves overall survival in patients with early-stage invasive melanoma.

True or False: Compared with...

02/13/2020

Oncology

Recent News

News

Nivolumab Plus Relatlimab Demonstrates Long-Term Efficacy, Safety Among Newly Diagnosed Patients With Advanced Unresectable Melanoma

08/19/2025

Stephanie Holland

According to results from the...

08/19/2025

Oncology

Conference Coverage

Neoadjuvant Pembrolizumab for Treatment-Naive Patients With Stage IIB/IIC Melanoma

06/17/2025

Stephanie Holland

According to results from a...

06/17/2025

Oncology

News

Adjuvant Pembrolizumab Continues to Prolong Survival Outcomes Among Patients With Stage IIB/IIC Melanoma

05/12/2025

Stephanie Holland

According to long-term follow-up results from the KEYNOTE-716 trial, adjuvant pembrolizumab continued to prolong survival outcomes among patients with stage IIB/IIC melanoma.

According to long-term follow-up...

05/12/2025

Oncology

News

Addition of Short-Term Targeted Therapy Provides Long-Term Survival Benefit for Patients With Advanced Melanoma

05/06/2025

Stephanie Holland

According to updated survival...

05/06/2025

Oncology

News

Tilsotolimod Plus Ipilimumab Fails to Significantly Improve Outcomes for Patients With Advanced Refractory Melanoma

04/11/2025

Stephanie Holland

According to results from the phase 3 ILLUMINATE-301 study, the addition of tilsotolimod to ipilimumab did not significantly improve outcomes among patients with advanced refractory melanoma.

According to results from the...

04/11/2025

Oncology

News

Pembrolizumab Plus Bevacizumab Shows Promise Among Previously Untreated Patients With Melanoma Brain Metastases

04/01/2025

Stephanie Holland

According to results from a phase 2 study, pembrolizumab plus bevacizumab demonstrated promise among previously untreated patients with melanoma brain metastases.

According to results from a...

04/01/2025

Oncology

News

Ipilimumab Plus Nivolumab Sustains Efficacy Among Patients With Asymptomatic Melanoma Brain Metastases

03/10/2025

Stephanie Holland

According to long-term follow-up...

03/10/2025

Oncology

News

Novel Engineered Toxin Body Targeting CTLA-4 Shows Potential Among Select Advanced Solid Tumors

03/06/2025

Allison Casey

According to a phase 1 trial, MT-8421, a novel ETB targeting CTLA4, demonstrated acceptable safety with no dose-limited toxicities among patients with select advanced solid tumors.

According to a phase 1 trial,...

03/06/2025

Oncology

News

Immunotherapy Plus Hypofractionated Radiotherapy Fails to Improve Survival for Treatment-Naive Melanoma

01/29/2025

Stephanie Holland

According to results from a phase 2 trial, immunotherapy plus hypofractionated radiotherapy did not improve survival among patients with treatment-naive metastatic melanoma.

According to results from a...

01/29/2025

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology

News

Genotype-Guided Therapy Demonstrates High Response and Survival Rates for Patients With R/R DLBCL

09/26/2025

Emily Estrada

The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.

The implementation of R-ICE...

09/26/2025

Oncology

News

PD-1/PD-L1 Inhibitor Monotherapy Demonstrates Accceptable Safety, Limited Efficacy for R/R DLBCL

09/26/2025

Emily Estrada

Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.

Treatment of R/R diffuse large...

09/26/2025

Oncology

News

Polatuzumab-Based Regimens Demonstrate Promising Efficacy for R/R DLBCL Compared to Traditional Salvage Therapies

09/26/2025

Emily Estrada

Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.

Compared with traditional...

09/26/2025

Oncology

FDA Approval

FDA Approves Imlunestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer

09/25/2025

Stephanie Holland

The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.

The FDA has approved...

09/25/2025

Oncology

News

Pexidartinib Shows Durable Response Among Patients with Tenosynovial Giant Cell Tumors

09/25/2025

Allison Casey

Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.

Pexidartinib showed sustained...

09/25/2025

Oncology

News

Clarithromycin-Based Quadruplet Therapy Demonstrates Promising Clinical Responses for Treatment of Relapsed/Refractory Multiple Myeloma

09/24/2025

Emily Estrada

For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.

For patients with...

09/24/2025

Oncology

News

First-Line mFOLFIRINOX, S-IROX Fail to Improve Survival Among Patients With Recurrent or Metastatic Pancreatic Cancer

09/23/2025

Stephanie Holland

Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...

Results from the phase 2/3...

09/23/2025

Oncology

News

Novel Anti-CSF1 Receptor Antibody for Patients With Tenosynovial Giant Cell Tumor

09/23/2025

Allison Casey

According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.

According to a phase 2a trial,...

09/23/2025

Oncology

News

Adverse Events With Pexidartinib for Patients With Tenosynovial Giant Cell Tumor

09/23/2025

Allison Casey

According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.

According to an analysis of the...

09/23/2025

Oncology

News

Trifluridine/Tipiracil Plus Bevacizumab Escalation Demonstrates Promise Among Patients With Advanced or Unresectable Metastatic Colorectal Cancer

09/22/2025

Stephanie Holland

According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...

According to results from the...

09/22/2025

Oncology